Virbac stock holds its outlook as half-year margins improve

Virbac stock (ISIN FR0000031577) closed at EUR 307.50 on Euronext Paris on September 21, 2026, down 2.38 percent over 52 weeks and 13.99 percent year to date. The veterinary pharmaceutical group reported 7.4 percent organic growth and an 18.8 percent operating margin for the first half of 2026, giving the stock a results-driven valuation test on September 22, 2026.

Half-year growth stays broad

According to Investir Les Echos on September 22, 2026, Virbac increased first-half revenue by 7.4 percent at constant scope and exchange rates. The operating margin reached 18.8 percent, 50 basis points higher than in the comparable period, while consolidated net profit rose 5.9 percent to EUR 87.1 million.

The comparison matters because growth was not confined to one customer group. Companion-animal sales increased 10 percent in the first half of 2026, while livestock-animal sales rose 6.7 percent, according to the same dated results report from Investir Les Echos.

Guidance raises the execution bar

Virbac is targeting the upper end of its full-year 2026 organic revenue-growth range of 5.5 percent to 7.5 percent at constant scope and exchange rates. The company also expects adjusted current operating profit to reach about 17 percent of revenue for fiscal year 2026, according to Zonebourse on September 22, 2026.

That target implies more than 100 basis points of margin improvement in the second half of 2026, compared with the 50 basis points delivered during the first half. The operating leverage requirement is therefore the central execution issue for the remainder of fiscal year 2026, even as the company maintains its revenue ambition.

Stock remains below yearly peak

Virbac traded at EUR 307.50 on September 21, 2026, according to the CAC Mid 60 component data. The same snapshot showed a 52-week high of EUR 389.50 and a 52-week low of EUR 297.00, placing the closing price EUR 82.00 below the high and EUR 10.50 above the low.

The share performance provides a counterweight to the operating figures: first-half organic growth was 7.4 percent and net profit advanced 5.9 percent, while the stock was down 13.99 percent year to date as of September 21, 2026. The gap between business growth and share performance leaves the market focused on whether the second-half margin target can be delivered.

Virbac stock closes at EUR 307.50

Virbac stock closed at EUR 307.50 on Euronext Paris on September 21, 2026. Its 52-week range was EUR 297.00 to EUR 389.50, with the latest close 21.05 percent below the yearly high.

More news and analyses on Virbac stock